These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Elevated levels of beta-catenin and fibronectin in three-dimensional collagen cultures of Dupuytren's disease cells are regulated by tension in vitro. Howard JC; Varallo VM; Ross DC; Roth JH; Faber KJ; Alman B; Gan BS BMC Musculoskelet Disord; 2003 Jul; 4():16. PubMed ID: 12866952 [TBL] [Abstract][Full Text] [Related]
11. Tamoxifen decreases fibroblast function and downregulates TGF(beta2) in dupuytren's affected palmar fascia. Kuhn MA; Wang X; Payne WG; Ko F; Robson MC J Surg Res; 2002 Apr; 103(2):146-52. PubMed ID: 11922728 [TBL] [Abstract][Full Text] [Related]
12. Post-transcriptional regulation of alpha-smooth muscle actin determines the contractile phenotype of Dupuytren's nodular cells. Verjee LS; Midwood K; Davidson D; Eastwood M; Nanchahal J J Cell Physiol; 2010 Sep; 224(3):681-90. PubMed ID: 20432463 [TBL] [Abstract][Full Text] [Related]
13. Fibroblasts from phenotypically normal palmar fascia exhibit molecular profiles highly similar to fibroblasts from active disease in Dupuytren's Contracture. Satish L; LaFramboise WA; Johnson S; Vi L; Njarlangattil A; Raykha C; Krill-Burger JM; Gallo PH; O'Gorman DB; Gan BS; Baratz ME; Ehrlich GD; Kathju S BMC Med Genomics; 2012 May; 5():15. PubMed ID: 22559715 [TBL] [Abstract][Full Text] [Related]
14. IGF-II and IGFBP-6 regulate cellular contractility and proliferation in Dupuytren's disease. Raykha C; Crawford J; Gan BS; Fu P; Bach LA; O'Gorman DB Biochim Biophys Acta; 2013 Oct; 1832(10):1511-9. PubMed ID: 23623986 [TBL] [Abstract][Full Text] [Related]
15. Expression of bone morphogenetic proteins by Dupuytren's fibroblasts. Shin SS; Liu C; Chang EY; Carlson CS; Di Cesare PE J Hand Surg Am; 2004 Sep; 29(5):809-14. PubMed ID: 15465229 [TBL] [Abstract][Full Text] [Related]
16. Beta-catenin expression in Dupuytren's disease: potential role for cell-matrix interactions in modulating beta-catenin levels in vivo and in vitro. Varallo VM; Gan BS; Seney S; Ross DC; Roth JH; Richards RS; McFarlane RM; Alman B; Howard JC Oncogene; 2003 Jun; 22(24):3680-4. PubMed ID: 12802275 [TBL] [Abstract][Full Text] [Related]
17. Developing an animal model of Dupuytren's disease by orthotopic transplantation of human fibroblasts into athymic rat. Satish L; Palmer B; Liu F; Papatheodorou L; Rigatti L; Baratz ME; Kathju S BMC Musculoskelet Disord; 2015 Jun; 16():138. PubMed ID: 26049932 [TBL] [Abstract][Full Text] [Related]
18. Involvement of pro-inflammatory cytokines and growth factors in the pathogenesis of Dupuytren's contracture: a novel target for a possible future therapeutic strategy? Bianchi E; Taurone S; Bardella L; Signore A; Pompili E; Sessa V; Chiappetta C; Fumagalli L; Di Gioia C; Pastore FS; Scarpa S; Artico M Clin Sci (Lond); 2015 Oct; 129(8):711-20. PubMed ID: 26201022 [TBL] [Abstract][Full Text] [Related]
19. Biochemical changes in the collagen of the palmar fascia in patients with Dupuytren's disease. Brickley-Parsons D; Glimcher MJ; Smith RJ; Albin R; Adams JP J Bone Joint Surg Am; 1981 Jun; 63(5):787-97. PubMed ID: 7240301 [TBL] [Abstract][Full Text] [Related]
20. Identification of histological patterns in clinically affected and unaffected palm regions in dupuytren's disease. Alfonso-Rodríguez CA; Garzón I; Garrido-Gómez J; Oliveira AC; Martín-Piedra MÁ; Scionti G; Carriel V; Hernández-Cortés P; Campos A; Alaminos M PLoS One; 2014; 9(11):e112457. PubMed ID: 25379672 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]